GleamWall
中文EN

MBRX Moleculin Biotech, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1659617 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY79.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-55.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets30.1%
Debt / equity0.00x
Current ratio1.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.37x
Accruals ratio76.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense$4.49M$5.45M$5.38M$5.12M$3.74M$3.60M$3.44M$4.46M
SG&A expense$2.11M$2.10M$2.49M$2.41M$2.15M$2.09M$2.48M$2.16M
Operating income-$6.61M-$7.56M-$7.87M-$7.53M-$5.91M-$5.72M-$5.94M-$6.64M
Income tax$0$0$0$0$0$0$0$0
Net income-$6.49M-$7.63M-$12.85M$15.55M-$25.40M-$17.81M-$5.90M-$6.58M
EBITDA-$6.60M-$7.55M-$7.87M-$7.52M-$5.88M-$5.69M-$5.91M-$6.61M
EPS (basic)-9.59-1.40-3.54—-340.43-28.68-15.80—
EPS (diluted)————————
Balance sheet
Cash & equivalents$7.29M$7.26M$10.32M$8.88M$6.70M$7.56M$7.72M$4.28M
Current assets$8.41M$8.72M$10.96M$9.69M$7.88M$9.08M$9.34M$5.19M
PP&E, net$54,000$62,000$70,000$78,000$77,000$99,000$127,000$159,000
Total assets$20.74M$21.09M$23.36M$22.13M$20.35M$21.59M$21.01M$16.93M
Current liabilities$6.13M$9.31M$7.96M$6.85M$5.68M$7.91M$6.90M$5.36M
Total liabilities$6.25M$9.50M$8.18M$7.12M$47.27M$25.18M$7.22M$5.72M
Shareholders' equity$14.49M$11.59M$15.18M$15.01M-$26.92M-$3.58M$13.79M$11.21M
Shares outstanding1.05M7.10M5.34M159,96149.50M30.21M14.13M135,155
Cash flow statement
Operating cash flow-$8.97M-$6.66M-$6.11M-$5.37M-$7.22M-$5.58M-$4.56M-$5.08M
Capital expenditure———$0$0$0$0$0
Free cash flow———-$5.37M-$7.22M-$5.58M-$4.56M-$5.08M
Investing cash flow$0$0$0$0$0$0$0$0
Financing cash flow$9.03M$3.61M$7.61M$7.49M$6.38M$5.42M$8.00M$1,000
Depreciation & amortization$8,000$8,000$8,000$9,000$21,000$29,000$31,000$31,000
Stock-based compensation$393,000$436,000$380,000$459,000$303,000$417,000$485,000$427,000

Free plan shows the latest 8 periods; Pro shows all 43 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.